|
2014 |
|
|
|
· Company name changed to CHA Biotech
· Equity Spin-off: CHA Diostech(Optical Business, KOSDAQ: 196450)
· Jong Soo Choi appointed as CEO
· Human embryonic stem cell derived RPE cell therapy for Stargardt Macular
Degeneration received Orphan Drug Designation(first in Korea)
· Phase I/IIa IND approval for Stroke received from MFDS in Korea(eCASs)
· CHA Biotech’s Cord Blood Bank, i-Cord, received 2014 The Customer
Trust Brand
Award(Hankyung Business)
· Injection to patients in phase I clinical trial for Stargardt Macular Degeneration
conducted in Korea completed(MA09-hRPE)
|
 |
 |
· Injection to 1st patient in phase I clinical trial for Stargardt Macular
Degeneration conducted in Korea completed(MA09-hRPE)
· Licensing Agreement between CHA Biotech and Pluristem Therapeutics in
Israel executed
· Physical Division: CHA Healthcare(Hospital Operation Business), CHA Meditech
(Bio Development Business)
· Asset Purchase Agreement with CMG Pharmaceutical executed
(Oral Thin Film Pharmaceutical)
|
|
|
|
2013
|
|
2012 |
|
|
|
· Phase I/IIa IND approval for Age-related Macular Degeneration(dry type)
received
from MFDS in Korea(MA09-hRPE)
· Injection to 1st patients in phase I/IIa clinical trial for Age-related Macular
Degeneration(dry type)conducted in Korea completed(MA09-hRPE)
· CMG Pharmaceutical(formerly, Sky New Pharm, KOSDAQ: 058820) acquired
· Won Suk Yang appointed as CEO
· Stem cell banking consignment agreement executed with Stem Union in
Hong Kong
|
|
· SCRMI, a US subsidiary company, succeeded to manufacture and induce
differentiation of world’s first platelets generated from human embryonic stem cells
· Phase I IND approval for Stargardt Macular Degeneration received from MFDS
in Korea(MA09-hRPE, World’s first ES cell therapy)
· Approval for establishment of private cord blood bank(i-cord) received from
MHW in Korea
· Recorded over 600 cases of cord blood transplant operation(first time in Korea)
· CHA Vaccine Institute(formerly, Dubeel) acquired
|
|
|
|
2011
|
|
|
|